Tumor-specific monoclonal antibodies (mAbs) offer several modes of tumor cell killing, from
direct cytotoxic activity to indirect mechanisms employing the host immune system …

Monoclonal antibodies constitute a major treatment option for many tumor patients. Due to
their specific recognition sites in their constant F c regions, antibodies are able to trigger …

With increasing evidence that complement activation significantly contributes to the
pathogenesis of a large number of inflammatory diseases, strategies that interfere with its …

Complement, as a central immune surveillance system, can be activated within seconds
upon stimulation, thereby displaying multiple immune effector functions. However, in …

Complement was initially discovered as an assembly of plasma proteins “complementing”
the cytolytic activity of antibodies. However, our current knowledge places this complex …

Although it was long believed that the complement system helps the body to identify and
remove transformed cells, it is now clear that complement activation contributes to …

Recently, there has been an increase of interest in the use of biological or immune-based
therapies for patients with malignancies. This has been informed by the deeper …

Monoclonal antibodies (mAb) have been used as targeted treatments against cancer for
more than a decade, with mixed results. Research is needed to understand mAb …

Complement is an important branch of innate immunity; however, its biological significance
goes far beyond the scope of simple nonspecific defense and involves a variety of …

Malignant cells are part of a complex network within the tumor microenvironment, where
their interaction with host cells and soluble mediators, including complement components, is …